5e70ba2109b32d0004a916bd_1.jpg
Todos Medical Provides Corporate Update
09 avr. 2020 09h03 HE | Todos Medical Ltd.
 Corona Diagnostics JV adds COVID-19 EUA-submitted point-of-care antibody test kit suppliers Ongoing pre-commercial clinical trial for TMB-1 and TMB-2 progressing despite COVID-19 Full acquisition of...
5e70ba2109b32d0004a916bd_1.jpg
Todos Medical Expands on Coronavirus (COVID-19) Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar
30 mars 2020 09h42 HE | Todos Medical Ltd.
 Todos expands rights to include Asian countries and to include PCR test kits Corona Diagnostics JV with Emerald Organic responsible for commercialization Dr. Joseph Wee, CEO of Todos Singapore,...
Alliance Funding Group Extends a $20 Million Sales Finance Line to Emerald Organic for Commercialization of its Proprietary, HIPAA Compliant Facial Recognition-enabled Vending Machines
05 mars 2020 09h34 HE | Emerald Organic Products Inc.
 $20M in sales finance secured from Alliance Funding Group to support initial equipment roll-out  Technology allows for the dispensing of a vast array of wellness products, including...
Emerald Organic Reaches Definitive Agreement for a $5 Million Injection of Private Equity Capital
03 mars 2020 10h22 HE | Emerald Organic Products Inc.
Funds will be used to fuel DTC growth and establish national retail presencePreferred Stock has fixed conversion price into common shares of $1.60 New York, NY, March 03, 2020 (GLOBE NEWSWIRE) --...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori
30 janv. 2020 09h05 HE | Amarantus Bioscience Holdings, Inc.
 Strong customer retention at both stores in Dallas, TX with growing online presence Focus  on delivering wellness solutions by engaging customers to participate in clinical studies and provide...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
02 janv. 2020 08h14 HE | Amarantus Bioscience Holdings, Inc.
 Emerald gains exclusive worldwide development rights to ESS, MANF and PhenoGuard Amarantus receives Emerald preferred stock valued at a minimum of $66.6 million New York, NY, Jan. 02,...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
24 oct. 2019 09h34 HE | Amarantus Bioscience Holdings, Inc.
 Amarantus is receiving Emerald Preferred Stock with a minimum value of $100M in 2022 Treatment candidates are for Alzheimer’s, ADHD, Parkinson’s, severe burns and vision loss Portfolio includes...